Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper.
作者信息
Dubeau Marie-France, Ghosh Subrata
机构信息
Inflammatory Bowel Disease Clinic Alberta IBD Consortium Gastroenterology Division, Department of Medicine University of Calgary Calgary, Alberta.
出版信息
Gastroenterol Hepatol (N Y). 2012 Feb;8(2):134-6.
Abstract
摘要
相似文献
1
Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper.优化英夫利昔单抗治疗炎症性肠病——工具正变得更加精准。
Gastroenterol Hepatol (N Y). 2012 Feb;8(2):134-6.
2
Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.比较英夫利昔单抗和阿达木单抗治疗炎症性肠病的药物生存情况。
Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31.
3
Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.英夫利昔单抗和/或免疫调节剂抑制炎症性肠病成人对三价流感疫苗的免疫应答。
J Crohns Colitis. 2014 Mar;8(3):223-33. doi: 10.1016/j.crohns.2013.08.008. Epub 2013 Sep 5.
4
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.优化抗TNF-α治疗：英夫利昔单抗和阿达木单抗的血清水平与炎症性肠病患者的黏膜愈合相关。
Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2. doi: 10.1016/j.cgh.2015.10.025. Epub 2015 Oct 29.
5
Factors associated with changes in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from a case management survey.
Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):1015-21. doi: 10.1586/17474124.2015.1044977. Epub 2015 Jun 11.
6
Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.在炎症性肠病治疗中使英夫利昔单抗毒性最小化。
Dig Liver Dis. 2008 Jul;40 Suppl 2:S236-46. doi: 10.1016/S1590-8658(08)60532-0.
7
Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.炎症性肠病：英夫利昔单抗治疗依从或不依从患者的医疗费用
J Med Econ. 2014 Jun;17(6):384-93. doi: 10.3111/13696998.2014.909436. Epub 2014 Apr 16.
8
[Infliximab in inflammatory bowel diseases--conference summary and suggested guidelines].[英夫利昔单抗治疗炎症性肠病——会议总结及建议指南]
Harefuah. 2006 Nov;145(11):844-9, 860.
9
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
10
Optimizing anti-TNF treatment in inflammatory bowel disease.优化炎症性肠病中的抗TNF治疗
Gastroenterology. 2004 May;126(6):1593-610. doi: 10.1053/j.gastro.2004.02.070.
引用本文的文献
1
Can molecular stratification improve the treatment of inflammatory bowel disease?分子分层能否改善炎症性肠病的治疗？
Pharmacol Res. 2019 Oct;148:104442. doi: 10.1016/j.phrs.2019.104442. Epub 2019 Sep 3.
本文引用的文献
1
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.英夫利昔单抗的 trough 水平和抗体可能无法预测炎症性肠病患者强化英夫利昔单抗治疗的反应。
Inflamm Bowel Dis. 2012 Jul;18(7):1199-206. doi: 10.1002/ibd.21839. Epub 2011 Aug 29.
2
Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.基于抗人λ链的酶联免疫吸附试验（ELISA）与双抗原 ELISA 检测抗英夫利昔单抗抗体的临床实用性比较。
Inflamm Bowel Dis. 2012 Sep;18(9):1628-33. doi: 10.1002/ibd.21919. Epub 2011 Oct 29.
3
A Crohn's disease patient who does not respond to infliximab: what is next?一位对英夫利昔单抗无反应的克罗恩病患者：接下来该怎么办？
Clin Gastroenterol Hepatol. 2011 Dec;9(12):1033-8. doi: 10.1016/j.cgh.2011.05.027. Epub 2011 Jun 6.
4
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.英夫利昔单抗谷浓度及抗英夫利昔单抗抗体在克罗恩病中的临界值水平与诊断准确性
Scand J Gastroenterol. 2011 Mar;46(3):310-8. doi: 10.3109/00365521.2010.536254. Epub 2010 Nov 18.
5
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?世界胃肠病学大会与欧洲克罗恩病和结肠炎组织关于 IBD 的生物治疗的伦敦立场声明：何时开始，何时停止，选择哪种药物，以及如何预测应答？
Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213. doi: 10.1038/ajg.2010.392. Epub 2010 Nov 2.
6
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.英夫利昔单抗的免疫原性部分是 F(ab')2，但检测完整英夫利昔单抗分子的抗体在临床上更有用。
Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.
7
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.血清白蛋白浓度：溃疡性结肠炎患者英夫利昔单抗药代动力学及临床反应的预测因素
Int J Clin Pharmacol Ther. 2010 May;48(5):297-308. doi: 10.5414/cpp48297.
8
Infliximab, azathioprine, or combination therapy for Crohn's disease.英夫利昔单抗、硫唑嘌呤或联合治疗克罗恩病。
N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
9
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.在炎症性肠病患者中测量英夫利昔单抗和人抗嵌合抗体浓度的临床实用性。
Am J Gastroenterol. 2010 May;105(5):1133-9. doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9.
10
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.经血清 infliximab 检测：infliximab 治疗急性溃疡性结肠炎临床结果的预测因子。
Gut. 2010 Jan;59(1):49-54. doi: 10.1136/gut.2009.183095.
Zotero 插件